Want to see PDSB full AI Analyst Report?
PDSB Stock Chart & Stats
$1.31
-$0.09(-5.36%)
At close: 4:00 PM EST
$1.31
-$0.09(-5.36%)
Day’s Range― - ―
52-Week Range$0.51 - $1.66
Previous CloseN/A
Volume197.50K
Average Volume (3M)1.09M
Market Cap
$47.62M
Enterprise Value$44.94M
Total Cash (Recent Filing)$21.66M
Total Debt (Recent Filing)$15.86M
Price to Earnings (P/E)―
Beta2.95
Next Earnings
Aug 18, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding55,815,655
10 Day Avg. Volume882,851
30 Day Avg. Volume1,094,799
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.61
Forecast
1Y Price Target
$9.00Price Target Upside587.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.55
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong IP ProtectionGranted U.S. and Japanese patents plus anticipated biologics exclusivity into the 2040s materially lengthen the period of exclusive commercialization for PDS0101. This durable IP barrier supports long-term pricing power, partner/licensing leverage, and downside protection vs. competitors for approved indications.
Manufacturing And CMC ReadinessAn established commercial manufacturing process and completed scale-up reduce execution risk ahead of a BLA. This structural readiness shortens time to market, lowers technical and supply risks, and improves credibility with regulators and partners, strengthening the firm's commercialization prospects.
Regulatory Pathway De‑risking Via Protocol AmendmentAdding PFS as an interim co-primary endpoint and reducing enrollment materially shortens trial duration and cost, increasing chance of an earlier accelerated approval. This structural protocol change improves probability and timing of a regulatory milestone rather than relying on only long-term OS outcomes.
Bears Say
High Leverage And Thin EquityA dramatic rise in debt and extremely thin equity in 2025 signal persistent balance-sheet fragility. High leverage increases refinancing risk, raises interest burdens, constrains strategic flexibility, and elevates dilution likelihood if capital markets are accessed to fund ongoing development.
Consistent Negative Cash GenerationSustained operating and free cash flow outflows indicate the business cannot self-fund development. Persistent cash burn makes the company dependent on external financing, which can dilute shareholders, restrict strategic options, and force prioritization of programs over the medium term.
Dependence On Confirmatory OS Data And Competitive RisksWhile interim PFS could enable accelerated approval, full commercial success hinges on OS confirmatory data, prolonging timelines and outcomes uncertainty. Coupled with competing Phase III programs and dependence on an anti‑PD‑1 partner, this increases execution and market share risk over the medium term.
PDS Biotechnology News
PDSB FAQ
What was Pds Biotechnology’s price range in the past 12 months?
Pds Biotechnology lowest stock price was $0.51 and its highest was $1.66 in the past 12 months.
What is Pds Biotechnology’s market cap?
Pds Biotechnology’s market cap is $47.62M.
When is Pds Biotechnology’s upcoming earnings report date?
Pds Biotechnology’s upcoming earnings report date is Aug 18, 2026 which is in 43 days.
How were Pds Biotechnology’s earnings last quarter?
Pds Biotechnology released its earnings results on May 13, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.01.
Is Pds Biotechnology overvalued?
According to Wall Street analysts Pds Biotechnology’s price is currently Undervalued.
Does Pds Biotechnology pay dividends?
Pds Biotechnology does not currently pay dividends.
What is Pds Biotechnology’s EPS estimate?
Pds Biotechnology’s EPS estimate is -0.13.
How many shares outstanding does Pds Biotechnology have?
Pds Biotechnology has 55,815,655 shares outstanding.
What happened to Pds Biotechnology’s price movement after its last earnings report?
Pds Biotechnology reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went up 20.909%.
Which hedge fund is a major shareholder of Pds Biotechnology?
Currently, no hedge funds are holding shares in PDSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PDS Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (587.02% Upside)
$9.00 (587.02% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.83%
12-Months-Change
Fundamentals
Return on Equity
-346.03%
Trailing 12-Months
Asset Growth
-47.56%
Trailing 12-Months
Company Description
Pds Biotechnology
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
PDSB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.View all PDSB earnings summariesPDSB Stock 12 Month Forecast
Average Price Target
$9.00
▲(587.02% Upside)
Technical Analysis
Ownership Overview
1.51%
Insiders
3.90% Mutual Funds
1.69% Other Institutional Investors
89.74% Public Companies and
Individual Investors